What's Next for Amarin's Stock?

Yesterday, Amarin (NASDAQ: AMRN) scored a major win. All 16 panelists on Vascepa's advisory committee voted in favor of the drug's cardioprotective benefit based on the unprecedented results of the cardiovascular outcomes study Reduce-It.